natgillin/translations-raw huggingface dataset:
90-graders vinkel i forhold til huden
90-degree angle to s
900 IE/1,08 ml
900 IU/1.08 mL
900 mg i den 3. uge, derefter 900 mg hver 2. uge
900 mg at week 3; then 900 mg every 2 weeks
900 mg i uge 3, derefter 900 mg hver 2. uge
900 mg at week 3; then 900 mg every 2 weeks
900 mg tabletter: - Karton med 5, 25 eller 50 tabletter i PVC/aluminium varmeforseglede blisterkort.
900 mg tablets: - Carton box with 5, 25 or 50 tablets in PVC/aluminium heat sealed blisters.
9000 IE /
9000 IU/0.9 ml
90429 Nürnberg Tyskland
90429 Germany
90429 Nürnberg Tyskland
D-90429 Nürnberg Germany
90min
90 min
90x1 filmovertrukne tabletter
84x1 film-coated tablets
90x1 filmovertrukne tabletter
90x1 film-coated tablets
90x1 filmovertrukne tabletter 100 filmovertrukne tabletter 100x1 filmovertrukne tabletter
90x1 film-coated tablets 100 film-coated tablets 100x1 film-coated tablets
90x1 tabletter (enhedsdosis)
90x1 tablets (unit dose)
90Y (yttrium-90) har en halveringstid på 2,67 døgn (64,1 timer).
90Y-yttrium has a half-life of 2.67 days (64.1 hours).
90° vinkel
90° angle
91 % af patienterne havde en ECOG-performancestatus ved baseline på 0 eller 1, og 9 % havde en ECOG- performancestatus på 2.
Ninety one percent of patients had a baseline ECOG performance status of 0 or 1 and 9% had an ECOG performance status of 2.
91 % og 93 % af de patienter, der fik initial behandling med henholdsvis febuxostat 80 mg og 120 mg, havde serumurat < 357 µmol/l (6 mg/dl) ved måned 36).
91% and 93% of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA <6 mg/dL at Month 36).
91,1 %) og flere behandlingsseponeringer på grund af bivirkninger (26,7 % vs.
91.1%, p=0.002*) and more discontinuations from the treatment due to adverse events (26.7% vs.
91,1 %, p=0,002*) og flere behandlingsseponeringer på grund af bivirkninger (26,7 % vs.
91.1%, p=0.002*) and more discontinuations from the treatment due to adverse events (26.7% vs.
91,4 (84,6; 95,3)
N=288 96.8 (94.0,
91,6 (12,19)
(N=123)
91070 Bondoufle Frankrig
91070 Bondoufle France
913 Efter kortvarig behandling (gennemsnitlig varighed 22 dage), var øget vægt ≥ 7 % af baseline legemsvægt (kg) var meget almindelig (40,6 %), ≥ 15 % af baseline legemsvægt var almindelig (7,1 %) og ≥25 % var almindelig (2,5%).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
92 % af enfuvirtid bindes til plasmaproteiner i hiv-inficeret plasma over en plasmakoncentrationsspændvidde fra 2 til 10 g/ml.
Enfuvirtide is 92% bound to plasma proteins in HIV infected plasma over a plasma concentration range of 2 to 10 g/ml.
92 mikrogram
92 micrograms
92 mikrogram /
92 micrograms /
92 myokardieinfarkter i placebogruppen over for 47 ud af 56 i eptifibatid-gruppen).
47 out of 56 MIs in the eptifibatide group).
92 patienter som fik docetaxel i kombination med trastuzumab.
92 patients treated with docetaxel in combination with trastuzumab.
92 patienter, som fik docetaxel i kombination med trastuzumab.
92 patients treated with docetaxel in combination with trastuzumab.
92%, og INCIVO må derfor ikke anvendes samtidig med rifampicin.
Therefore, INCIVO must not be co-administered with rifampicin.
92,3 (11,96)
(N=111)
92,8 % til 98,6 %
92.8% to 98.6
92,9 % til 98,0 %
92.9% to 98.0
92289 Ursensollen Tyskland
92289 Ursensollen Germany
927, 2005: Appendix serological criteria for calculation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. reduktion i risikoen for første episode af klinisk pneumoni med unormalt røntgenbillede af brystet (defineret som tilstedeværelsen af infiltrater, effusion eller fortætning) 35% (95% CI: 4, 56).
In the per-protocol analysis, the estimated risk reduction for the first episode of clinical pneumonia with abnormal chest radiograph (defined as the presence of infiltrates, effusion or consolidation) was 35 % (95 % CI: 4, 56).
92800 - Puteaux Frankrig
92800 - Puteaux France
93 af disse patienter havde sygdommen på et fremskredet stadium og var resistente over for anden behandling.
Ninety-three of these patients had advanced disease that had not responded to other treatment.
93% af patienterne, som fik Simponi i starten af den åbne studieforlængelse (uge 16), forblev i behandling til og med afslutningen af studiet (uge 52).
At week 52, patients entered an open label long-term extension.
93,2 % af patienterne fik ASA samtidigt plus thienopyridin-behandling, og 6.8 % fik ASA alene.
93.2 % of patients received ASA concomitantly plus thienopyridine treatment and 6.8 % ASA only.
93,6 (11,71)
(N=105)
93,9 (12,66)
(N=120)
93,9 (13,20)
(N=123)
94 % og 0,4 % blev genfundet i fæces og urin.
[14C]-radioactivity was 95%, consisting of approximately 94% and 0.4% recovered from the faeces and urine, respectively.
94 (83,9%) patienter randomiseret til BAT-armen krydsede over til ruxolitinib-behandling ved uge 32 eller senere, hvilket begrænser sammenligningen af de to arme efter uge 32.
94 (83.9%) patients randomised to the BAT arm crossed over to ruxolitinib treatment at Week 32 or after, limiting the comparison between the two arms after Week 32.
94 af 107 børn var inkluderet i det opfølgende 5-årige langtidsstudie.
Ninety-four of 107 subjects enrolled in the 5 year long-term follow-up trial.
94,0 % havde hudlæsioner ved baseline, og 37,6 % havde renal angiomyolipom-læsioner (mindst et angiomyolipom ≥1 cm for den længste diameter).
94.0% had skin lesions at baseline and 37.6% had target renal angiomyolipoma lesions (at least one angiomyolipoma ≥1 cm in longest diameter).
94,1 %
N=27
94,1 (11,42)
(N=111)
94,3 % til 98,9 %
94.3% to 98.9
94,42 %B)
94.42% B)
94,9 (77,7 til 117,0)
94.9 (77.7 to 117.0)
941,4 mg paraffinolie
941.4 mg liquid paraffin
94250 Gentilly Frankrig
94250 Gentilly France
9490 Vaduz, Liechtenstein
9490 Vaduz, Fürstentum LIECHTENSTEIN
95 %
95% CI
95 % af dosis udskilles i urinen som lacosamid og metabolitter.
95% of the dose is excreted in the urine as drug and metabolites.
95 % af hundene vendte tilbage til normale plasmatestosteronniveauer inden for 2,5 år efter implantation.
95 % of dogs had returned to normal plasma testosterone levels within 2.5 years of implantation.
95 % CI
(%)
95 % CI
0.68-0.93
95 % CI
95 % C.I.
95 % CI 0,25-0,49; p<0,00001), og derudover identificerede forudplanlagte undergruppeanalyse af BRCA-mutationsstatus patienter med BRCA-muteret ovariecancer (n=136, 51,3 %), som den undergruppe, der fik den største kliniske fordel af vedligeholdelsesmonoterapi med olaparib.
0.25-0.49; p<0.00001), moreover, pre-planned subgroup analysis by BRCA-mutation status identified patients with BRCA-mutated ovarian cancer (n=136, 51.3%) as the subgroup that derived the greatest clinical benefit from olaparib maintenance monotherapy.
95 % CI af gennemsnit **
95% CI of mean
95 % CI af ORR
95% CI of ORR
95 % CI for median
95% CI for median
95 % CI for median (dage)
95% CI for median (days)
95 % CI for rate5
95% CI of Rate5
95 % CI p-værdi†*
95% CI
95 % CI*
95% CI
95 % CI:
95% CI: 1.05,
95 % CIa
95% CIa
95 % konfidensinterval
(95 % CI)
95 % konfidensinterval (%)
95% CI (%)
95 % konfidensinterval (0,56-0,76)
95% CI (0.56; 0.76)
95 % konfidensinterval (0,69-0,93)
95% CI (0.69; 0.93)
95 % konfidensinterval for binomial fordeling for en prøve (one sample binomial) beregnet efter Pearson- Clopper-metoden.
95% CI for one sample binomial using Pearson-Clopper method.
95 % konfidensinterval for forskel på responsrate4
95% CI for Difference in Response Rates4
95 % konfidensinterval for forskellen i procentdele
95% confidence interval for the for the difference in proportions
95 % konfidensinterval for hazard ratio
95% confidence interval for the hazard ratio
95 % konfidensinterval for responsrate3
95% CI for Response Rates3
95 % konfidensinterval kunne ikke fastslå (enkelt-emne data)
95% Confidence Interval could not be established (single-subject data)
95 % konfidensintervaller beregnet som LS Mean  1,96  Standard Error.
95% confidence intervals calculated as LS Mean  1.96  Standard Error.
95 % konfidensintervaller.
95% confidence intervals.
95 % konfidensintervallet inkluderede en hazard ratio på 1 for alle undergrupperne.
The 95 % confidence intervals for all subgroups include a hazard ratio of 1.
95 % præcis CI
95% Exact CI
95 % tosidet CI for behandlingsforskel (Eurartesim - Komparator), p-værdi
95 % two-sided CI on the treatment difference (Eurartesim - Comparator); p-value
95 %-CI = 1,08-2,26; p = 0,0018).
CI = 1.08 - 2.26, p = 0.018).
95 %-CI for HR
95 % CI for HR
95 %-CI for HR
95% CI for HR
95 %-CI for HR
Abbreviation: CI = confidence interval
95 %-CI for median
95 % CI for median
95 %-CI for median
95% CI for median
95 %-KI
87.1, 100.0
95 %-KI
95% CI
95 %-konfidensintervallet er anført i "[]"
The 95% confidence interval is stated in ‘[]’
95 %CI
95% CI
95 af disse patienter havde ikke responderet på hverken fludarabin eller alemtuzumab, og 112 patienter havde ikke responderet på behandling med fludarabin, men var ikke blevet behandlet med alemtuzumab, da dette lægemiddel ikke var egnet til dem.
In 95 of these patients, the disease had not responded to both fludarabine and alemtuzumab, and in 112, treatment with fludarabine had failed but they had not been treated with alemtuzumab because this medicine was not suitable for them.
95 mg/23,75 mg hårde kapsler med modificeret udløsning
95 mg/23.75 mg modified-release hard capsule
95 mg/23,75 mg hårde kapsler med modificeret udløsning
95 mg/23.75 mg modified-release hard capsules
95 mg/23,75 mg: hård kapsel med modificeret udløsning
95 mg/23.75 mg modified-release hard capsule
95 ml oral opløsning (1 flaske) Oral sprøjte
95 ml oral solution (1 bottle) Oral syringe
95% af de nukleos(t)id-naive patienter, 84% af de nukleos(t)idbehandlede patienter og 83% af de lamivudin-resistente patienter opnåede HBV-dna < 400 kopier/ml ved uge 72.
Ninety-five percent of nucleos(t)ide-naïve patients, 84% of nucleos(t)ide- experienced patients, and 83% of lamivudine-resistant patients achieved HBV DNA < 400 copies/ml at week 72.
95% af dosis udskilles i urinen som lacosamid og metabolitter.
95% of the dose is excreted in the urine as drug and metabolites.
95% CI (0,30; 0,60)
95% CI (0.30, 0.60) p-value < 0.0001
95% CI for forskel
95% CI for difference
95% CI for hazard ratio (0,4316 til 0,6430) p-værdia <0,0001
95% CI for hazard ratio (0.4316 to 0.6430) p-valuea <0.0001
95% CI for hazard ratio (0,6730 til 1,0013) p-værdi a 0,0510
95% CI for hazard ratio (0.6730 to 1.0013) p-value a 0.0510
95% CI for median (dage)
95% CI for median (days)
95% CI: 3,8; 24,6
95% CI: 3.8, 24.6
95% CI: 6,2; 32,0
95% CI: 6.2, 32.0
95% CI: 8,7;49,1
7/33 (21.2%)
95% konfidensinterval for hazard ratio
95% CI for Hazard ratio
95% konfidensinterval for objektiv responsrate Komplet respons
Responders*** 95% CI for ORR
95% konfidensinterval for objektiv responsratec
(95% CI) for ORRc
95% konfidensinterval for overordnet respons
95 % CI for overall
95% konfidensintervaller
95% confidence intervals
95% konfidensintervaller for moder-til-barn overførselsrater var 5,4 –19,3% (stavudin), 5,2 – 18,7% (didanosin); 1,3 – 11,2% (stavudin + didanosin); og 1,9 – 12,6% for zidovudin.
95% Confidence intervals for the mother-to-child-transmission rates were 5.4-19.3% (stavudine), 5.2-18.7% (didanosine); 1.3-11.2% (stavudine + didanosine); and 1.9-12.6% for zidovudine.
95%-konfidensintervallet er anført i "[]"
The 95% confidence interval is stated in ‘[]’
95,1%b konfidensinterval (3,2%; 24,3%) a
95.1%b CI (3.2%, 24.3%) a
95,3 % konfidensinterval (%)
95.3% CI (%)
95,9 % til 99,9 %
95.9% to 99.9
95-200 Pabianice Polen
95-200 Pabianice Poland
96 % af patienterne i begge behandlingsgrupper gennemførte studiet i overensstemmelse med protokollen og den vitale status var kendt i afslutningen af studiet for 99,0 % og 98,6% af patienterne i hhv. lixisenatid- og placebogruppen.
Ninety-six percent of the patients in both treatment groups completed the study in accordance with the protocol and the vital status was known at the end of the study for 99.0% and 98.6% of the patients in the lixisenatide and placebo group, respectively.
96 % af patienterne på dabrafenib- monoterapi i den integrerede sikkerhedspopulation og alle patienter på kombinationsterapi i fase III- studiet, der udviklede cuSCC, fortsatte i behandling uden dosisjustering.
Ninety-six percent of patients on dabrafenib monotherapy in the integrated safety population and all patients on combination therapy in the Phase III studies who developed cuSCC continued on treatment without dose modification.
96 % betablokkere, 33 % calciumantagonister diltiazem og verapamil, og 4 % digoxin).
96% beta blockers, 33% calcium channel blockers diltiazem and verapamil, and 4% digoxin).
96 %, 91 % og 82 %.
96 %, 91 % and 82 %, respectively.
96 (4 x 24 x 1) kapsler
96 (4 x 24 x 1)
96 (4x24x1) kapsler
96 (4x24x1) capsules (unit
96 kapsler
96 capsules
96 tabletter
96 tablets
96 til 114
96 to 114
96% af simeprevir-udvalgte genotype 1-replikoner bar en eller flere aminosyresubstitutioner ved NS3- protease-positionerne 43, 80, 155, 156 og/eller 168, hvor substitutioner ved NS3-position D168 var hyppigst observeret (78%).
Ninety-six percent of simeprevir-selected genotype 1 replicons carried one or multiple amino acid substitutions at NS3 protease positions 43, 80, 155, 156, and/or 168, with substitutions at NS3 position D168 being most frequently observed (78%).
96%; p=0,017) men ikke i det tredobbelte immunosuppressive forsøg (94% vs.
96%; p = 0.017), but not in the triple immunosuppressant trial (94% Vs.
96,0 til 10,8
96.0 (10.8)
96,0 til 9,7
96.0 (9.7)
96,1)
NA
96,3 til 12,2
96.3 (12.2)
96,85% CI (0,43; 0,81) p-værdi 0,0002
96.85% CI (0.43, 0.81) p-value 0.0002
97 % af de patienter (37 ud af 39 patienter behandlet med teduglutid), som gennemførte det placebokontrollerede studie, indgik i et langvarigt forlængelsesstudie, hvor alle patienter fik 0,05 mg Revestive/kg dagligt i op til yderligere 2 år.
Ninety-seven percent of patients (37 out of 39 patients treated with teduglutide) that completed the placebo-controlled study entered a long-term extension study where all patients received 0.05 mg/kg of Revestive daily for up to an additional 2 years.
97 % af de patienter, der gennemførte de randomiserede studier med partielle anfald, blev inkluderet i det åbne forlængelsesstudie (n=1.186).
Ninety-seven percent of the patients who completed the randomised trials in patients with partial onset seizures were enrolled in the open label extension study (n=1186).
97,5 %-konfidensintervaller benyttes ved de primære effektmål (samlet SVR12-rate); 95 %- konfidensintervaller benyttes ved yderligere effektmål (SVR12-rater hos HCV genotype 1a- og 1b- smittede patienter).
97.5% confidence intervals are used for the primary efficacy endpoints (overall SVR12 rate); 95% confidence intervals are used for additional efficacy endpoints (SVR12 rates in HCV genotype 1a and 1b-infected subjects).
9785-CL-0222 (TERRAIN)-studiet (kemoterapi-naive patienter)
9785-CL-0222 (TERRAIN) study (chemotherapy-naïve patients)
98 % af alle forsøgspatienter, som fik palivizumab, gennemførte studiet, og 97% fik alle 5 injektioner.
Ninety-eight percent of all subjects receiving palivizumab completed the study and 97% received all five injections.
98 (2 x 49 x 1) tabletter
98 (2 x 49 x 1) tablets
98 (2 x 49 x 1) tabletter (enhedsdosis) (multipakning)
98 (2 x 49 x 1) tablets (unit dose) (multipack)
98 (2 x 49 x 1) tabletter (multipakning)
98 (2 x 49 x 1) tablets (multipack)
98 (2 x 49) kapsler
98 (2 x 49) capsules
98 (2 x 49) tabletter (multipakning)
98 (2 x 49) tablets (multipack)
98 (2x49) tabletter
98 (2x49) tablets
98 (2x49) tabletter (multipakning)
98 (2x49) tablets (multipack)
98 (2x49) tabletter (multipakninger)
98 (2x49) tablets (multipack)
98 (2x49x1) tabletter (multipakning)
98 (2x49x1) tablets (multipack)
98 (2x49x1) tabletter (multipakning) (enkeltdosis)
98 (2x49x1) tablets (multipack) (unit dose)
98 depottabletter
98 prolonged-release tablets
98 filmovertrukne tabletter (kalenderpakning)
98 film-coated tablets (calendar blister)
98 filmovertrukne tabletter i kalenderblistere
98 film-coated tablets in calendar blisters
98 filmovertrukne tabletter.
98 film-coated tablets
98 hårde kapsler
98 hard capsules
98 overtrukne tabletter
98 coated tablets
98 smeltetabletter
98 orodispersible tablets
98 tabletter
84 tablets
98 tabletter
EU/1/12/755/017 [98 tablets]
98 tabletter
EU/1/12/755/026 [98 tablets]
98 tabletter
EU/1/12/756/017 [98 tablets]
98 tabletter
OTHER (FOR CALENDARISED PACKS)
98 tabletter (2x49, PA/Alu/PVC blister)
98 tablets (2x49, PA/Alu/PVC blisters)
98 tabletter (multipakning)
98 tablets (multipack)
98 tabletter (PVC/PCTFE blister)
98 tablets (PVC/PCTFE blisters)
98 tabletter med modificeret udløsning.
98 modified-release tablets.
98 tabletter.
98 tablets.
98 tabletter: EU/1/08/480/006
98 tablets: EU/1/08/480/006
98 tabletter: EU/1/10/632/007
98 tablets: EU/1/10/632/007
98 tabletter: EU/1/10/632/014
98 tablets: EU/1/10/632/014
98 tabletter: EU/1/10/632/021
98 tablets: EU/1/10/632/021
98 tabletter: EU/1/11/721/007
98 tablets: EU/1/11/721/007
98 tabletter: EU/1/11/721/014
98 tablets: EU/1/11/721/014
98 tabletter: EU/1/11/721/021
98 tablets: EU/1/11/721/021
98 tabletter: EU/1/11/723/007
98 tablets: EU/1/11/723/007
98 tabletter: EU/1/11/723/014
98 tablets: EU/1/11/723/014
98 tabletter: EU/1/11/723/021
98 tablets: EU/1/11/723/021
98 x 1 filmovertrukne tabletter
98 x 1 film-coated tablets
98 x 1 filmovertrukne tabletter.
98 x 1 Film-coated tablets
98 x 1 filmovertrukne tabletter.
98 x 1 Film-coated tablets.
98 x 1 tablet (enhedsdosis)
98 x 1 tablet (unit dose)
98 x 1 tablet (enhedsdosis)
98 x 1 tablets (unit dose)
98 x 1 tablet (enkeltstyk)
98 x 1 tablet (unit dose)
98 x 1 tabletter
98 x 1 tablets
98 x 1 tabletter
98 x 1 tablets (unit
98 x 1 tabletter (enhedsdosis)
98 x 1 tablets (unit dose)
98 x 1 tabletter (enkeltdosis)
98 x 1 tablets (unit dose)
98 x 1 tabletter (multipakning)
98 x 1 tablets (multipack)
98 x tabletter (multipakning)
98 x 1 tablets (multipack)
98) dispergible tabletter.
98) dispersible tablets.
98,3)
N/R
980 (10 x 98) tabletter
980 (10 x 98) tablets
980 Great West Road
980 Great West Road Brentford
980 Great West Road, Brentford, Middlesex TW8 9GS Storbritannien
980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom
980 Great West Road, Brentford, Middlesex TW8 9GS, Storbritannien
980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom.
980 Great West Road, Brentford, Middlesex, TW8 9GS Storbritannien
980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom
980 tabletter (10 x 98 tabletter)
980 tablets (10 x 98 tablets)
98x1 filmovertrukne tabletter.
98 x 1 Film-coated tablets.
99 % af patienterne (243/246), der var indskrevet i STS fase III-studiet, inklusive de 15 forsøgspersoner, fik antracyklin.
99 % of patients (243/246) enrolled in the STS phase III study, including the 15 subjects, received anthracycline.
99 patienter blev behandlet med MabThera, og 12% oplevede mindst én infusionsrelateret reaktion.
Ninety nine patients were treated with MabThera and 12% experienced at least one IRR.
99 tabletter
99 tablets
99 x 106 celler/l
99 x 106 cells/l
99-300 Kutno Polen
99-300 Kutno Poland
999 mg metaflumi-zon og 999 mg amitraz
999 mg metaflumizone and 999 mg amitraz
99mTc-depreotid anbefales ikke anvendt til patienter under 18 år, da der ikke foreligger data for denne aldersgruppe.
99mTc-depreotide is not recommended for use in patients below the age of 18 as data are not available for this age group.
99mTc-depreotid er derfor kontraindiceret ved graviditet. (Se punkt 4.3)
99mTc-depreotide is therefore contraindicated in pregnancy. (See section 4.3)
99mTc-depreotid er kun til enkelt administration.
99mTc-depreotide is indicated for single use only.
< 0,0001 (1-sidet og 2-sidet)
< 0.0001 (1-sided and 2-sided)
< 0,001c
< 0.001c
< 0,32 mmol/l (1,0 mg/dl), skal Stribild seponeres.
< 0.32 mmol/L (1.0 mg/dL) then Stribild should be discontinued.
< 0,5 x 109/l til > 5,0 x 109/l.
< 0.5 x 109/L to > 5.0 x 109/L.
< 0,5 x 109/l, kan eltrombopag genstartes ved den tidligere effektive dosis.
< 0.5 x 109/L, eltrombopag may be reinitiated at the previous effective dose.
< 1 %); Misfarvning af negle; Onycholysis (G3/4: 1 %)
Nail discolouration; Onycholysis (G3/4: 1%)
< 1 log10 reduktion i HCV- RNA i uge 4
< 1 log10 reduction in HCV RNA at week 4
< 1 nmol hemicystin/mg protein.
< 1 nmol hemicystine/mg protein.
< 1,0 x 109/l
1.0 x 109/l
< 1,467 mmol/l) op til (≥ 1,467 mmol/l).
< 1.467 mmol/l) to high (≥ 1.467 mmol/l).
< 1,467 mmol/l), steg til høje (≥ 1,467 mmol/l).
< 1.467 mmol/l) to high (≥ 1.467 mmol/l).
< 1-log10 fald
< 1-log10 decline
< 1.0 x 109/l og/eller trombocytter
< 1.0 x 109/L and/or platelets
< 1.500, men
< 1,500 but
< 1/1.000)
Arthralgia
< 1/1.000) og meget sjælden (< 1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
< 1/1,000) very rare (< 1/10,000), not known (cannot be estimated from the available data).
< 1/1.000), meget sjælden (< 1/10.000) eller ikke kendt (kan ikke estimeres ud fra forhåndenværende data)
<1/1,000), very rare (<1/10,000), not known (cannot be estimated from available data).
< 1/1.000), meget sjælden (< 1/10.000) eller ikke kendt (kan ikke estimeres ud fra forhåndenværende data)
<1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
< 1/1.000), meget sjælden (< 1/10.000) og ikke kendt (kan ikke estimeres ud fra de foreliggende data).
< 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
< 1/1.000), meget sjælden (< 1/10.000) og ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
<1/10), uncommon (1/1,000, < 1/100), rare (1/10,000, < 1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
< 1/1.000), meget sjælden (< 1/10.000), herunder isolerede indberetninger.
< 1/1,000); very rare (< 1/10,000), including isolated reports.
< 1/1.000), meget sjælden (< 1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
< 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
< 1/1.000); meget sjælden (< 1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
< 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
< 1/10) og ikke almindelig (≥ 1/1.000 til < 1/100).
(≥ 1/1,000 to < 1/100).
< 1/10), ikke almindelig (≥ 1/1.000 til < 1/100), sjælden (≥ 1/10.000 til < 1/1.000), meget sjælden (< 1/10.000) og ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
<1/1,000), very rare (<1/10,000), and not known (cannot be estimated from the available data).
< 1/10); ikke almindelig (≥ 1/1.000 til < 1/100); sjælden (≥ 1/10.000 til < 1/1.000); meget sjælden (< 1/10.000); hyppighed ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
< 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
< 1/10); ikke almindelig (≥ 1/1.000 til <1/100); sjælden (≥ 1/10.000 til < 1/1.000); meget sjælden (< 1/10.000).
Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100 Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000).
< 1/10); ikke almindelig (≥ 1/1.000 til <1/100); sjælden (≥ 1/10.000 til < 1/1.000); meget sjælden (< 1/10.000).
Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000).
< 1/10); ikke almindelig (≥ 1/1.000 til <1/100); sjælden (≥ 1/10.000 til < 1/1.000); meget sjælden (< 1/10.000).
Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000).
< 1/10); ikke almindelig (≥ 1/1.000 til <1/100); sjælden (≥ 1/10.000 til < 1/1.000); meget sjælden (< 1/10.000).
Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000);.